Compare PMCB & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | SCNI |
|---|---|---|
| Founded | 1996 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | PMCB | SCNI |
|---|---|---|
| Price | $0.94 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 41.7K |
| Earning Date | 12-15-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.01 | ★ 0.26 |
| Revenue | N/A | ★ $1,147,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $162.06 | ★ $4.55 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $0.63 | $0.86 |
| 52 Week High | $1.90 | $6.18 |
| Indicator | PMCB | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 38.13 |
| Support Level | $0.71 | $1.14 |
| Resistance Level | $1.51 | $1.26 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 33.08 | 13.13 |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.